Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. By demonstrating a significant reduction in the relative risk of a renal-specific composite endpoint, Invokana became the first antidiabetic drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial. The SGLT-2 inhibitor has opened the door for this drug class to be used to lower eGFR limits, potentially shifting treatment patterns in this market. Likewise, in 2021, Bayer’s Kerendia became the first mineralocorticoid receptor antagonist approved by the FDA to slow the progression of DN.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AstraZeneca, Johnson and Johnson, Eli Lilly
Key drugs: Farxiga, Invokana, Jardiance
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.